Our findings suggested that genetically predicted SGLT2 inhibition played a causal role in reducing the risk of several malignancies, including oropharyngeal cancer, bronchial and lung cancer, rectal cancer, ovarian cancer, non-melanoma skin cancer, and multiple myeloma. This evidence concerns the gene SLC5A2 and plasma cell myeloma.